- Lobbying
- pain AND therapeutics
Lobbying Arrangements Results for 'Pain Therapeutics'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Issues related to abuse-resistant drug products. |
PAIN THERAPEUTICS, INC.
|
ARNOLD & PORTER LLP | |||
Details Issues related to Medicare Part B reimbursement for pain therapies. Issues regarding pain therapies. |
TerSera Therapeutics
|
Thorn Run Partners | |||
Details Issues related to treatment and management of pain and the FDA drug approval process Issues related to treatment and management of pain |
Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a biopharmaceutical company. |
JEFFREY J. KIMBELL & ASSOCIATES, INC. | |||
Details FDA oversight of certain pain reliever products. |
Law Office of John M. Quinn (on behalf of Nektar Therapeutics)
|
NVG, LLC | |||
Details Education and support for public policies that promote the development, use, coverage and reimbursement of novel, non-opioid pain therapies. |
Flexion Therapeutics, Inc.
|
COVINGTON & BURLING LLP | |||
Details FDA oversight of certain pain reliever products. |
QGA Public Affairs (on behalf of Nektar Therapeutics)
|
NVG, LLC | |||
Details Develop and execute a government relations strategy relating to Allay Therapeutics agenda and new drug application (NDA). |
Allay Therapeutics
|
BUCHANAN INGERSOLL & ROONEY PC | |||
Details FDA oversight of certain pain reliever products. |
Manatt, Phelps and Phillips, LLP (on behalf of Nektar Therapeutics)
|
NVG, LLC | |||
Details Healthcare, Medicare (specific issues related to fair competition, the generic drug market, drug costs, pain management, COVID) |
Tauzin Consultants (on behalf of Sorrento Therapeutics Inc)
|
Tauzin Strategic Networks | |||
Details FDA oversight of certain pain-reliever products |
Nektar Therapeutics
|
QGA Public Affairs (formerly Quinn Gillespie & Associates) | |||
Details Prescription drug abuse, misuse, and diversion Development of abuse-deterrent drug formulations Implementation of P.L. 110-85/HR 3580, Food and Drug Administration Amendments Act of 2007 (section o... |
Pain Therapeutics Inc.
|
PATTON BOGGS LLP | |||
Details Coverage for substance abuse and mental health services in legislation to repeal/replace the Affordable Care Act (American Health Care Act HR 1628); adequacy of health care coverage for pain therap... |
Pernix Therapeutics Holdings, LLC
|
Knight Capitol Consultants | |||
Details Advocated for federal funding to support development of neuroactive steroids research yielding therapeutics with a core focus on Traumatic Brain Injury (TBI), Post-Traumatic Stress Disorder (PTSD),... |
Sage Therapeutics, Inc.
|
PETRIZZO BOND, INC. | |||
Details H.R. 5809, Postoperative Opioid Prevention Act of 2018 H.R. 6, SUPPORT for Patients and Communities Act (provisions relating to incentives for post-surgical, non-opioid pain management treatments) |
Farragut Partners LLP on behalf of Heron Therapeutics
|
Capitol Hill Strategies, LLC | |||
Details FDA oversight of certain pain reliever products |
Nektar Therapeutics
|
Manatt, Phelps, and Phillips | |||
Details implementation of the "No Pain" Act; Hospital Outpatient Prospective Payment System; MIPS quality program; |
Omeros Corporation
|
Lester Health Law PLLC | |||
Details Issues related to fair competition, the generic drug market, drug costs, pain management, non-opioid alternatives, and prior authorization. Also issues related to COVID-19. |
Scilex Holding Company
|
Tauzin Consultants, LLC | |||
Details Promoting non-opioid pain management alternatives. |
Sorrento Therapeutics, Inc.
|
STONINGTON GLOBAL | |||
Details Issues related to antibiotics. |
Medicis Pharmaceutical Corporation
Specialty pharmaceutical company. |
Arnold & Porter LLP | |||
Details Issues related to Medicare and Medicaid access to non-opioid treatment for chronic pain. H.R.1458 / S.723 - Access to Prescription Digital Therapeutics Act of 2023. |
Averitas Pharma, Inc
|
Thorn Run Partners | |||
Details Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies ... |
Vertex Pharmaceuticals Incorporated
|
STANTON PARK GROUP |